Sickle Cell Anemia Testing and Screening Market, By Testing Method (Hemoglobin Electrophoresis, High-Performance Liquid Chromatography (HPLC), Point-of-Care Tests, Genetic Testing, and Others), By Age Group (Newborn Screening, Ages 1 to 25, and Ages 26 an

Sickle Cell Anemia Testing and Screening Market, By Testing Method (Hemoglobin Electrophoresis, High-Performance Liquid Chromatography (HPLC), Point-of-Care Tests, Genetic Testing, and Others), By Age Group (Newborn Screening, Ages 1 to 25, and Ages 26 and Above), By Sector (Government Labs, Private Labs, Corporate Labs, and PPP), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Sickle cell anemia is a genetic blood disorder that affects the red blood cells and causes them to take on a C-like or sickle shape. It is a group of disorders that causes the red blood cells to become misshapen and break down leasing to anemia. The disorder is more common in those with ancestry from sub-Saharan Africa, Latin America, Central America, and India. With increased immigration and travel globally, its prevalence has increased in diverse populations as well. Early screening programs can help in the management of the condition and prevent complications through lifelong treatment and monitoring.

Market Dynamics:

The global sickle cell anemia testing and screening market is driven by the increasing prevalence of the genetic blood disorder globally. In October 2021, as per the World Health Organization (WHO), it is estimated that over 300,000 children are born with sickle cell anemia each year. Growing awareness among at-risk populations and incorporating screening in prenatal testing are providing lucrative opportunities in the market. However, lower adoption and awareness levels in developing regions continues to restrain the market growth. Developments in precision medicine and non-invasive testing techniques can help overcome challenges and further expand the market reach during the forecast period.

Key Features of the Study:

• This report provides in-depth analysis of the global sickle cell anemia testing and screening market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global sickle cell anemia testing and screening market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Agios Pharmaceuticals, Inc., Bluebird bio, Inc., PerkinElmer, Inc., Laboratory Corporation of America Holdings, Global Blood Therapeutics, Inc., Edvotek Inc., Maternova Inc., Hemex Health, CRISPR Therapeutics, Anamol Laboratories Pvt. Ltd., Atlas Medical GmbH, and Calibre Scientific, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global sickle cell anemia testing and screening market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sickle cell anemia testing and screening market

Market Segmentation

• By Testing Method Insights (Revenue, USD Mn, 2019 - 2031)
• Hemoglobin Electrophoresis
• High-Performance Liquid Chromatography (HPLC)
• Point-of-Care Tests
• Genetic Testing
• Others
• By Age Group Insights (Revenue, USD Mn, 2019 - 2031)
• Newborn Screening
• Ages 1 to 25
• Ages 26 and Above
• By Sector Insights (Revenue, USD Mn, 2019 - 2031)
• Government Labs
• Private Labs
• Corporate Labs
• PPP (Public Private Partnerships)
• Regional Insights (Revenue, USD Mn, 2019 - 2031)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Agios Pharmaceuticals, Inc.
• Bluebird bio, Inc.
• PerkinElmer, Inc.
• Laboratory Corporation of America Holdings
• Global Blood Therapeutics, Inc.
• Edvotek Inc.
• Maternova Inc.
• Hemex Health
• CRISPR Therapeutics
• Anamol Laboratories Pvt. Ltd.
• Atlas Medical GmbH
• Calibre Scientific, Inc.